Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2001

View Archived Issues

Lexicon Genetics reaches milestone in drug development alliance with Bristol-Myers Squibb

Phase II clinical data for secretin presented at Autism Society meeting

Elan licenses European rights to DepoCyte from SkyePharma

Thalomid to be submitted for new indication this year

Two recent clinical studies do not support the use of dopamine D1/5 antagonists in cocaine abuse

Randomized trial shows that cranberry juice prevents recurrence of UTI

Safety and efficacy of finasteride similar in younger and older men

Proton pump inhibitors provide the best heartburn relief

Medarex enters antibody collaboration with Human Genome Sciences

Prana Biotechnology awarded a START grant for AD drug development

OxyContin labeling changes reflect new FDA warnings

ViaCell acquires Cerebrotec

Feasibility of s.c. vaccination with VAQTA demonstrated

Head-to-head osteoporosis fracture study comparing Evista and Fosamax

Immediate pain following i.m. injection of QS-21 may be alleviated with certain excipients

Stand-alone package of Rebetol approved in U.S.

FDA advisory committee does not recommend approval of Symlin

MedImmune begins additional study of siplizumab in psoriasis patients

Two new Zonagen erectile dysfunction products evaluated in phase II trials

CancerVax to seek marketing approval of Canvaxin melanoma vaccine in Canada

New anticoagulants particularly suited for thrombosis and heparin-associated thrombocytopenia

Agouron's new rotamase-inhibitory neurotrophic agents

New adenosine derivatives with cardiac effects reported by CV Therapeutics

Selective JNK modulators and their use described by ARS

Abbott patents new series of peptide angiogenesis inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...